ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2539

Patient-reported outcomes in patients with polymyalgia rheumatica under rheumatology care: baseline data from the ENRICH-PMR cohort
Abstract Number: 2540

Monocyte-to-High-Density Lipoprotein Cholesterol Ratio as a Clinical Marker of Gastrointestinal Involvement in Behçet Syndrome
Abstract Number: 2541

Development of Severity Classification Criteria for Introduction of Infliximab for Chronic Pogressive Neuro-Behçet’s Disease
Abstract Number: 2542

A Rule Based NLP Pipeline for Glucocorticoid exposure
Abstract Number: 2543

Severe Visual Impairment in Behçet Syndrome in Time: A Comparison of Four Time Periods
Abstract Number: 2544

Diagnostic value of vein wall thickness measurement for patients with suspected Behçet syndrome
Abstract Number: 2545

Prevalence, Clinical Correlations and Outcomes of Cryoglobulinemic Vasculitis: a Retrospective Monocentric Study (2013–2023)
Abstract Number: 2546

Diagnostic Journey, Clinical Burden, And Quality Of Life Of Patients With IGg4-Related Disease: Results Of A Cross-Sectional Survey Of Patients And Physicians In The United States
Abstract Number: 2547

Assessing the Reach of a Virtual Education Program: Lupus & You: Answers. Advocacy. Action.
Abstract Number: 2548

Management of Uncontrolled Gout Among Rheumatologists: Findings from a Medical Chart Audit
Abstract Number: 2549

Perceived Dignity in Patients With Rheumatic Disease
Abstract Number: 2550

Development of a ‘Training Toolkit’ to Support Advanced Practice Providers (APPs) Entry into a Rheumatology Musculoskeletal Ultrasound Subspecialty Clinic
Abstract Number: 2551

Integrating Advanced Practice Providers into a Rheumatology Musculoskeletal Ultrasound Clinic: Enhancing Patient Access and Procedural Expertise
Abstract Number: 2552

Effects of 360° Virtual Reality Embodiment Videos on Pain in Hand Osteoarthritis: A Within-Subject Pre-Post Study
Abstract Number: 2553

Impact of Polypharmacy on Treatment Adherence and Its Effect on The Quality of Life in Patients with Rheumatic Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].